Parkinsonism & related disorders最新文献

{"title":"(IN)VISIBLE ZEBRAS IN PLAIN SIGHT","authors":"F. Trpcheski , A. Angelova , G. Novotni","doi":"10.1016/j.parkreldis.2025.107864","DOIUrl":"10.1016/j.parkreldis.2025.107864","url":null,"abstract":"","PeriodicalId":19970,"journal":{"name":"Parkinsonism & related disorders","volume":"135 ","pages":"Article 107864"},"PeriodicalIF":3.1,"publicationDate":"2025-05-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144166626","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"POLG-Associated Mitochondrial Disorder Manifesting as Severe Hemidystonia","authors":"S. Anis","doi":"10.1016/j.parkreldis.2025.107862","DOIUrl":"10.1016/j.parkreldis.2025.107862","url":null,"abstract":"","PeriodicalId":19970,"journal":{"name":"Parkinsonism & related disorders","volume":"135 ","pages":"Article 107862"},"PeriodicalIF":3.1,"publicationDate":"2025-05-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144166227","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effect of periodical continuous theta burst stimulation in Parkinson's disease","authors":"Xin Chen ,&nbsp;Tingting Liu ,&nbsp;Mengqi Wang ,&nbsp;Jinmei Sun ,&nbsp;Jinying Han ,&nbsp;Liuzhenxiong Yu ,&nbsp;Ziye Zhao ,&nbsp;Pingping Liu ,&nbsp;Lili Hu ,&nbsp;Minhao Zhu ,&nbsp;Jingjing Cheng ,&nbsp;Rong Ye ,&nbsp;Gongjun Ji ,&nbsp;Kai Wang ,&nbsp;Panpan Hu","doi":"10.1016/j.parkreldis.2025.107897","DOIUrl":"10.1016/j.parkreldis.2025.107897","url":null,"abstract":"<div><h3>Background</h3><div>Previous studies have demonstrated that repetitive transcranial magnetic stimulation (rTMS) can improve clinical symptoms of Parkinson's disease (PD). Continuous theta-burst stimulation (cTBS) is a well-established rTMS protocol that affects brain neurons, reducing the excitability of the motor system.</div></div><div><h3>Objectives</h3><div>This study aims to explore the long-term effects of cTBS on improvement of movement symptoms in patients with PD.</div></div><div><h3>Methods</h3><div>Patients who met the inclusion criteria were non-randomly assigned to either the cTBS group or control group. The cTBS group received rTMS interventions every 10 weeks, while the control group was treated solely with anti-Parkinson's medications for symptom management. The study cycle lasted nearly one year, with data analysis conducted from March to May 2024. Linear mixed models were employed to analyze the primary outcome using the Unified Parkinson's Disease Rating Scale (UPDRS) Part III.</div></div><div><h3>Results</h3><div>A total of 43 participants completed the 46-week study. The cTBS group demonstrated significant improvement in UPDRS III compared to the control group after the first intervention, maintaining this progress until the final follow-up, which correlated with changes in overall motor symptoms. Additionally, the cTBS group showed a significant decrease in H-Y scale, while the levodopa equivalent dose (LED) did not increase significantly.</div></div><div><h3>Conclusions</h3><div>These findings implicated that cTBS can effectively alleviate motor symptoms of PD, and rTMS targeting left SMA may be a feasible and easy-to-implement non-drug intervention to slow the progressive decline in motor symptoms and quality of life in PD, providing a new option for PD treatment.</div></div>","PeriodicalId":19970,"journal":{"name":"Parkinsonism & related disorders","volume":"136 ","pages":"Article 107897"},"PeriodicalIF":3.1,"publicationDate":"2025-05-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144196425","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reply to the letter by Xin-Tao and Qiuhan XU","authors":"Francisco Eduardo Costa Cardoso ,&nbsp;Perola Oliveira","doi":"10.1016/j.parkreldis.2025.107893","DOIUrl":"10.1016/j.parkreldis.2025.107893","url":null,"abstract":"","PeriodicalId":19970,"journal":{"name":"Parkinsonism & related disorders","volume":"137 ","pages":"Article 107893"},"PeriodicalIF":3.1,"publicationDate":"2025-05-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144226200","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Predictors of discontinuation in foslevodopa/foscarbidopa therapy for Parkinson's disease","authors":"Noriko Nishikawa ,&nbsp;Taku Hatano ,&nbsp;Daiki Kamiyama ,&nbsp;Hikaru Kamo ,&nbsp;Yutaka Oji ,&nbsp;Chihiro Abe ,&nbsp;Junko Shinada ,&nbsp;Genko Oyama ,&nbsp;Nobutaka Hattori","doi":"10.1016/j.parkreldis.2025.107896","DOIUrl":"10.1016/j.parkreldis.2025.107896","url":null,"abstract":"","PeriodicalId":19970,"journal":{"name":"Parkinsonism & related disorders","volume":"136 ","pages":"Article 107896"},"PeriodicalIF":3.1,"publicationDate":"2025-05-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144147821","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"No one size fits all approach with apomorphine initiation.","authors":"Christopher Kobylecki, Richard J B Ellis","doi":"10.1016/j.parkreldis.2025.107889","DOIUrl":"https://doi.org/10.1016/j.parkreldis.2025.107889","url":null,"abstract":"<p><p>Continuous subcutaneous apomorphine infusion (CSAI) is an important treatment for motor fluctuations in the complex phase of Parkinson's disease (PD). Several barriers to accessing CSAI exist, including perceptions of how treatment initiation should occur. The majority of published work on CSAI initiation reports inpatient admission for this treatment, but restrictions on access to inpatient hospital beds may limit availability. We review here the evidence for different approaches, including published work on outpatient/daycase or home CSAI treatment initiation. Whereas inpatient initiation allows faster titration of CSAI treatment, home initiation has been found to allow effective and safe treatment initiation and offers potential cost savings. Complication rates in all approaches appear comparable, although the overall clinical profile and comorbitidities of patients should be taken into account when deciding on the best method of initiation. A flexible approach to CSAI initiation has potential benefits to people with PD in terms of better access.</p>","PeriodicalId":19970,"journal":{"name":"Parkinsonism & related disorders","volume":" ","pages":"107889"},"PeriodicalIF":3.1,"publicationDate":"2025-05-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144226199","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Response to letter to the Editor: The association between cigarette smoking and dementia with Lewy bodies.","authors":"Anna E Goodheart, Stephen N Gomperts","doi":"10.1016/j.parkreldis.2025.107895","DOIUrl":"https://doi.org/10.1016/j.parkreldis.2025.107895","url":null,"abstract":"","PeriodicalId":19970,"journal":{"name":"Parkinsonism & related disorders","volume":" ","pages":"107895"},"PeriodicalIF":3.1,"publicationDate":"2025-05-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144249148","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cerebral amyloid angiopathy in patients with Dementia with Lewy Bodies: A clinical and hippocampal morphology study","authors":"Caroline Hall ,&nbsp;Paolo Salvioni Chiabotti ,&nbsp;Giulia Bommarito ,&nbsp;Yasser Alemán-Goméz ,&nbsp;Sabrina Carlier ,&nbsp;Mirco Nasuti ,&nbsp;Daniel Damian ,&nbsp;Mario Jreige ,&nbsp;Vincent Dunet ,&nbsp;Olivier Rouaud ,&nbsp;Patric Hagmann ,&nbsp;Olaf Blanke ,&nbsp;Alessandra Griffa ,&nbsp;Gilles Allali","doi":"10.1016/j.parkreldis.2025.107892","DOIUrl":"10.1016/j.parkreldis.2025.107892","url":null,"abstract":"<div><h3>Introduction</h3><div>Dementia with Lewy Bodies (DLB) is often associated with Cerebral Amyloid Angiopathy (CAA) based on pathological studies. Current literature in DLB reveals heterogenous findings regarding CAA effects on cognition, but overall suggests a diffuse impact on different cognitive domains, depending in parts on CAA severity. Reduced hippocampal volumes have also been reported in CAA patients. This study aims first at reporting the prevalence of CAA in DLB according to the Boston Criteria 2.0, and second at analyzing the impact of CAA on neuropsychological performances and hippocampal volumes in DLB patients.</div></div><div><h3>Method</h3><div>We retrospectively evaluated the prevalence of CAA in DLB patients followed at the Leenaards Memory Center (Lausanne University Hospital, Lausanne, Switzerland) with the Boston Criteria version 2.0 and compared cognitive performance and hippocampal volumes between DLB+CAA and DLB-CAA patients.</div></div><div><h3>Results</h3><div>87 DLB patients (77.5 ± 7.2yo; 34.5 % females) were included. We found that 65.5 % of DLB patients presented with any (probable + possible) CAA. Cognitive performances and hippocampal volumes (total and segmentation) were similar between both groups.</div></div><div><h3>Conclusion</h3><div>This study shows that the presence of CAA does not impact cognition and hippocampal volume in patients with DLB.</div></div>","PeriodicalId":19970,"journal":{"name":"Parkinsonism & related disorders","volume":"137 ","pages":"Article 107892"},"PeriodicalIF":3.1,"publicationDate":"2025-05-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144222218","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Defining 'OFF' time in device-aided therapy criteria for Parkinson's disease: gaps and opportunities.","authors":"Roongroj Bhidayasiri, Phooi Leng Lean, K Ray Chaudhuri","doi":"10.1016/j.parkreldis.2025.107894","DOIUrl":"https://doi.org/10.1016/j.parkreldis.2025.107894","url":null,"abstract":"<p><p>Evaluating individuals with Parkinson's to determine if they have progressed to the advanced stage and may be suitable for transitioning from intermittent oral medications to continuous, device-aided therapy (DAT) involves considering multiple clinical factors. A key parameter in this assessment, and an indicator of a declining response to oral medication, is overall daily OFF time and the occurrence of unpredictable OFF episodes. OFF-periods are, however, complex and experienced differently by individual patients, so assessment of duration alone may not provide an accurate picture of the patient's lived experience and the challenges they face, information which can be helpful in deciding appropriate management. A range of useful screening tools are available to assist clinicians in determining if a patient has advanced disease and may be suitable for DAT, but these do not always capture the aspects of OFF periods that are the most important, or the most bothersome, to patients. To improve recognition, enhance patient-clinician communication, and achieve effective, personalized management of OFF periods, we propose expanding these tools to consider additional dimensions in three specific areas. First, incorporate patient insights into the personal and functional impact, including the severity of OFF periods, effects on daily activities, and the types and timing (daytime or nighttime) of episodes. Second, include specialist advice from clinicians to characterise the nature of these symptoms and determine suitable therapies. Finally, support this with objective information from PD diaries or technology-based monitoring.</p>","PeriodicalId":19970,"journal":{"name":"Parkinsonism & related disorders","volume":" ","pages":"107894"},"PeriodicalIF":3.1,"publicationDate":"2025-05-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144216552","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Diagnostic accuracy of screening tools for depression and anxiety in cervical dystonia","authors":"Davide Martino ,&nbsp;Mehrafarin Ramezani ,&nbsp;Steven Bellows ,&nbsp;Brian D. Berman ,&nbsp;Florence Ching-Fen Chang ,&nbsp;Jeanne Feuerstein ,&nbsp;Victor Fung ,&nbsp;Gamze Kilic Berkmen ,&nbsp;Irene A. Malaty ,&nbsp;Claire MacIver ,&nbsp;Scott A. Norris ,&nbsp;Kathryn J. Peall ,&nbsp;Joel S. Perlmutter ,&nbsp;Sarah Pirio Richardson ,&nbsp;Laura J. Wright ,&nbsp;Zahra Goodarzi ,&nbsp;Hyder A. Jinnah","doi":"10.1016/j.parkreldis.2025.107891","DOIUrl":"10.1016/j.parkreldis.2025.107891","url":null,"abstract":"<div><h3>Introduction</h3><div>Despite their high prevalence and impact, depression and anxiety are not routinely screened for, and accuracy of screening procedures is unknown in adult-onset dystonia. We evaluated accuracy parameters of selected self-rated scales for depression and anxiety in patients with idiopathic cervical dystonia (CD).</div></div><div><h3>Methods</h3><div>Two-hundred-and-ten patients with idiopathic CD were recruited from 10 movement disorders centers from the US, Canada, Australia, and UK. At the end of each botulinum toxin cycle, participants were administered the Adult Standard Mini-International Neuropsychiatric Interview (MINI) as reference standard for depression and anxiety. Participants completed 8 self-administered index instruments (2 for depression, 2 for anxiety, and 4 combining screening for both). Sensitivity, specificity, positive and negative predictive values, covariate-adjusted area under the receiver operating characteristic curve (AUC), and likelihood ratios were calculated for all instruments.</div></div><div><h3>Results</h3><div>On the MINI, 8.6 % (100 % female) fulfilled criteria for current major depressive disorder and 10.5 % (91 % female) fulfilled criteria for any current disorder amongst panic, social anxiety or generalized anxiety disorders. For depression screening, all tools had an AUC higher than 0.80, with the two most accurate being the BDI-II (AUC 0.91, sensitivity 87.5 %) and the HADS-Depression (AUC 0.88, sensitivity 93.7 %). For anxiety screening, the only instrument showing clinical usefulness was the HADS-Anxiety (AUC 0.82, sensitivity 86.3 %).</div></div><div><h3>Conclusion</h3><div>Current major depression can be screened in CD with high degree of accuracy using different self-administered scales, whereas existing screening tools for anxiety perform worse. Dystonia-specific instruments are less accurate than scales developed for the general population.</div></div>","PeriodicalId":19970,"journal":{"name":"Parkinsonism & related disorders","volume":"136 ","pages":"Article 107891"},"PeriodicalIF":3.1,"publicationDate":"2025-05-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144167585","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}